Sažetak
Uvod/Cilj. Dijabetesna polineuropatija (DPN) je veoma česta, progredijentna bolest koja dovodi do grubog urušavanja kvaliteta života praćenog visokom stopom invalidnosti. Iz tih razloga ispitivanje terapijskih sredstava za ovu bolest je u zamahu. Metode. Ispitivani su najčešće korišćeni lekovi za dijabetesnu neuropatiju u našem podneblju, uz elektrofiziološko praćenje da bi se izbegla subjektivnost i „placebo efekat“. Kod ukupno 120 bolesnika podeljenih u četiri grupe ispitivana je alfa lipoinska kiselina, benfotiamin i gabapentin, s tim što je elektrofiziološki praćena i grupa bolesnika koji u posmatranom periodu nisu dobijali terapiju. Analizirali smo motornu brzinu provođenja, distalnu latencu, senzitivnu brzinu provođenja, F talas i hronodisperziju F talasa, pre i posle terapije za svako pojedinačno terapijsko sredstvo. Rezultati. Evidentno je da su neki lekovi imali povoljan uticaj na stanje perifernog nerva. Alfa lipoinska kiselina i benfotiamini su imali uticaja na oporavak nerva odnosno patofiziološke procese, gabapentin je bio bez uticaja na oporavak, a slično je bilo i kod kontrolne grupe koja je bila bez bilo kakve terapije. Elektrofiziološki pokazatelji su imali različitu osetljivost na detekciju stanja perifernog neurona. Najbolji efekat koji se ogleda u povećanju senzitivne brzine provođenja imali su bolesnici koji su tretirani alfalipoičnom kiselinom. Zaključak. Uticaj alfa lipoinske kiselina i benfotiamina na stanje perifernog nerva je evidentno. Odsustvo oporavka, odnosno pogoršanje elektrofizioloških pokazatelja kod ispitanika koji nisu dobijali neuroprotektivnu terapiju, ukazuje na potrebu permanentne medikacije i periodičnog elektrofiziološkog praćenja bolesnika sa dijabetesnom polineuropatijom.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Vinik AI. Management of neuropathy and foot problems in diabetic patients. Clin Cornerstone 2003; 5(2): 38−55.
Vinik AI, Mitchell BD, Leichter SB, Wagner AL, O'Brian JT, Georges LP. Epidemiology of the complications of diabetes. In: Leslie RD, Robbins DC, editors. Diabetes Clinical Science in Practice. Cambridge, United Kingdom: Cambridge University Press; 1995. p. 221−87.
Hotta N, Tojota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al. Clinical efficacy of fidarestat, a novel aldose reductase in-hibitor, for diabetic peripheral neuropathy: a 52-week multi-center placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24(10): 1776−82.
Pluijms W, Huygen F, Cheng J, Mekhail N, van Kleef M, Van Zundert J, et al. Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy. Pain Pract 2011; 11(2): 191−8.
American Diabetes Association. Standards of medical care in di-abetes-2012. Diabetes Care 2012; 35 Suppl 1: S11−63.
Greene DA, Stevens MJ, Feldman EL. Glycemic control. In: Dyck PJ, Thomas PK, editors. Diabetic Neuropathy. 2nd ed. Philadel-phia: W.B. Saunders Company; 1999. p. 297−315.
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropa-thy. Cochrane Database Syst Rev 2012; 6: CD007543.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. European ederation of Neurological Societies. EFNS guide-lines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17(9): 1113−e88.
Dworkin RH, Connor AO, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132(3): 237−51.
Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Glei-ter CH. Comparative bioavailability of two vitamin B1 prepara-tions: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 1997; 52(4): 319−20.
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycem-ic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9(3): 294−9.
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfo-tiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116(10): 600−5.
Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med 2010; 68(4): 158−62.
Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud 2009; 6(4): 230−6.
Shaikh AS, Somani RS. Animal models and biomarkers of neu-ropathy in diabetic rodents. Indian J Pharmacol 2010; 42(3): 129−34.
Dordević G, Durić S, Apostolskit S, Dordević V, Zivković M. Total antioxidant blood capacity in patients with type 2 diabetes mel-litus and distal symmetrical polyneuropathy. Vojnosanit Pregl 2008; 65(9): 663−9. (Serbian)
Ewing DJ, Clarke BF. Diabetic autonomic neuropathy, present insights and future prospects. Diabetes Care 1986; 9(6): 648−65.
Cryer FE. Atherogenic hypoglycemia in IDDM. Consequences, risk factors and prevention.In: Home PD, Marshall S, Alberti KG, Krall L, editors. Diabetes Annual. Amsterdam: Elsevier; 1993. p. 317−31.
Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and anti-oxidant defense in relation to the severity of diabetic polyneu-ropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27(9): 2178−83.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006; 29(11): 2365−70.
Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: A critical review. Treat Endocrinol 2004; 3(3): 173−89.
Várkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013; 19(27): 4981−5007.
Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, et al. The effects of long-term oral benfotiamine supplementa-tion on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: A 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012; 35(5): 1095−7.